New option for macular oedema patients
Posted: Wednesday 31 August 2016Pharmaceutical company Bayer’s drug Eylea will be offered as a starting point for patients with certain forms of macular oedema.
The National Institute for Health and Care Excellence (NICE) has released a draft recommendation of the anti-VEGF drug